Frequently Asked Questions
The market is segmented based on , By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, and Others), Dosage (150mg/single-dose vial and 420mg/multidose vial), End-Users (Specialty Clinics, Hospitals, Oncology Centers, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2030.
.
The Global Herceptin Biosimilars Market size was valued at USD 1810.00 USD Million in 2022.
The Global Herceptin Biosimilars Market is projected to grow at a CAGR of 23.2% during the forecast period of 2023 to 2030.
The major players operating in the market include Amgen , AryoGen Pharmed, Biocon, Accord Healthcare Ltd, Celltrion Healthcare Co., Pfizer , Merck Sharp & Dohme Corp., Shanghai Henlius Biotech, Gedeon Richter Plc., Genor Biopharma Company Ltd, MABION S.A, Mylan N.V., F. HoffmannLa Roche Ltd, Samsung Bioepis, ACROBiosystems, Genentech, AstraZeneca, Halozyme, Teva Pharmaceuticals USA, .
The market report covers data from the U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa..
